These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26923188)

  • 1. Design of a RANK-Mimetic Peptide Inhibitor of Osteoclastogenesis with Enhanced RANKL-Binding Affinity.
    Hur J; Ghosh A; Kim K; Ta HM; Kim H; Kim N; Hwang HY; Kim KK
    Mol Cells; 2016 Apr; 39(4):316-21. PubMed ID: 26923188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis.
    Ta HM; Nguyen GT; Jin HM; Choi J; Park H; Kim N; Hwang HY; Kim KK
    Proc Natl Acad Sci U S A; 2010 Nov; 107(47):20281-6. PubMed ID: 21059944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis.
    Jules J; Shi Z; Liu J; Xu D; Wang S; Feng X
    J Biol Chem; 2010 Nov; 285(48):37427-35. PubMed ID: 20870724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
    Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
    Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis.
    Wang Y; van Assen AHG; Reis CR; Setroikromo R; van Merkerk R; Boersma YL; Cool RH; Quax WJ
    FEBS J; 2017 Aug; 284(15):2501-2512. PubMed ID: 28627025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization.
    Jiang M; Peng L; Yang K; Wang T; Yan X; Jiang T; Xu J; Qi J; Zhou H; Qian N; Zhou Q; Chen B; Xu X; Deng L; Yang C
    J Med Chem; 2019 Jun; 62(11):5370-5381. PubMed ID: 31082234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function.
    Warren JT; Zou W; Decker CE; Rohatgi N; Nelson CA; Fremont DH; Teitelbaum SL
    J Cell Biochem; 2015 Nov; 116(11):2476-83. PubMed ID: 25864714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
    Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
    Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL.
    Jang Y; Sohn HM; Ko YJ; Hyun H; Lim W
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An LGR4 agonist activates the GSK‑3β pathway to inhibit RANK‑RANKL signaling during osteoclastogenesis in bone marrow‑derived macrophages.
    Jang Y; Lee H; Cho Y; Choi E; Jo S; Sohn HM; Kim BC; Ko YJ; Lim W
    Int J Mol Med; 2024 Jan; 53(1):. PubMed ID: 38063193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
    Rahman MM; Bhattacharya A; Fernandes G
    J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway.
    Zhao H; Lazarenko OP; Chen JR
    J Cell Physiol; 2020 Jan; 235(1):599-610. PubMed ID: 31271661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Aggarwal BB
    Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.